Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30245% above fair value
$4.59−0.09 (-1.89%)
Close on Nov 17, 2026Market cap $63.91MP/E –Yield –
Champions Oncology r&d expenses
Research and development expenses are spending on new products and technology.
Champions Oncology's R&D Expenses for the twelve months ending Jul 31, 2026 was $9.35M, up 25.4% year over year. For fiscal 2026 it was $9.08M, up 33.1% from the year before. Over ten years it grew 8.0% a year on average. The highest annual figure on record is $11.55M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $9.08M | +33.1% |
| FY2025 | Apr 30, 2025 | $6.83M | -28.5% |
| FY2024 | Apr 30, 2024 | $9.54M | -17.3% |
| FY2023 | Apr 30, 2023 | $11.55M | +23.2% |
| FY2022 | Apr 30, 2022 | $9.37M | +30.3% |
| FY2021 | Apr 30, 2021 | $7.20M | +22.9% |
| FY2020 | Apr 30, 2020 | $5.85M | +22.0% |
| FY2019 | Apr 30, 2019 | $4.80M | +9.0% |
| FY2018 | Apr 30, 2018 | $4.40M | +2.5% |
| FY2017 | Apr 30, 2017 | $4.29M | +2.4% |
| FY2016 | Apr 30, 2016 | $4.19M | -13.4% |
| FY2015 | Apr 30, 2015 | $4.85M | +113.9% |
| FY2014 | Apr 30, 2014 | $2.27M | +18.0% |
| FY2013 | Apr 30, 2013 | $1.92M | -34.6% |
| FY2012 | Apr 30, 2012 | $2.94M | +0.9% |
| FY2011 | Apr 30, 2011 | $2.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $2.34M | +12.6% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | $2.12M | +7.7% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $2.27M | +32.1% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $2.62M | +54.9% |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | $2.08M | +43.2% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $1.96M | -4.2% |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $1.72M | -21.4% |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | $1.69M | -32.8% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $1.45M | -47.9% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | $2.05M | -28.1% |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | $2.19M | -31.7% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $2.52M | -3.4% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | $2.79M | -3.3% |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | $2.85M | +10.1% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $3.20M | +46.8% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $2.60M | +13.3% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | $2.89M | +25.3% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $2.59M | +25.1% |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $2.18M | +16.1% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $2.30M | +39.3% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $2.30M | +44.3% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | $2.07M | +13.9% |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $1.88M | +35.1% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $1.65M | +23.0% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $1.60M | +22.6% |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | $1.82M | +45.7% |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $1.39M | +9.6% |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $1.34M | +12.4% |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | $1.30M | +19.8% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | $1.25M | +14.2% |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | $1.27M | +21.4% |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $1.19M | +7.0% |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $1.09M | -2.7% |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | $1.09M | +1.6% |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $1.05M | +4.7% |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $1.12M | +10.6% |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | $1.12M | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | $1.08M | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | $998.00K | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $1.01M | – |
See a number that looks wrong?